<DOC>
	<DOCNO>NCT02713802</DOCNO>
	<brief_summary>Evaluate pharmacokinetic/pharmacodynamic equivalence safety tolerability single dos Cudafol ( R ) Diprivan ( R ) healthy subject .</brief_summary>
	<brief_title>Pilot Study Bioequivalence Cudafol ( R ) Diprivan ( R ) Administered Single Intravenous Doses Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Propofol</mesh_term>
	<criteria>Nonobese men woman , 18 55 year age inclusive , good health determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test screen . Females childbearing potential must use approved contraceptive method . Evidence history clinically significant disease . History presence clinically significant abnormal 12lead electrocardiogram ( ECG ) , blood pressure , heart rate . Pregnant nursing ( lactate ) woman . Known hypersensitivity allergy propofol ( component either formulation , include egg , soybean oil betadex sulfobutyl ether sodium ) form anesthesia , reaction anesthesia past . Family history malignant hyperthermia . History drug alcohol abuse ( test positive screening ) current smoker . Poor venous access either arm . Tests positive hepatitis B surface antigen , hepatitis C virus antibody , human immunodeficiency virus antibody . Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>